Adeno-Associated Virus (AAV) Antibody Study in Subjects OTC Deficiency, GSDIa, and Wilson Disease
Observational Clinical Study of Anti-AAV Seroprevalence in Subjects With Ornithine Transcarbamylase Deficiency, Glycogen Storage Disorder Type Ia, and Wilson Disease
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Rio Grande Do Sul
-
Porto Alegre, Rio Grande Do Sul, Brazil, 90560-030
- Hospital de Clinicas de Porto Alegre
-
-
-
-
Quebec
-
Montréal, Quebec, Canada, H4A 3J1
- McGill University Health Center
-
-
-
-
-
Santiago De Compostela, Spain, 15706
- Hospital Clinico Universitario de Santiago de Compostela
-
-
-
-
-
Hexham, United Kingdom, NE46 1QJ
- Synexus North East Clinical Research Centre
-
-
-
-
Ohio
-
Akron, Ohio, United States, 44311
- Synexus Clinical Research US (Virtual Trial)
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Diagnosis of OTC deficiency, GSDIa, or Wilson Disease.
- Provide informed consent after the nature of the study has been explained, and prior to any research-related procedures.
Exclusion Criteria:
- Prior exposure to an AAV-based gene therapy.
- Concurrent or previous participation in another Ultragenyx clinical study.
- Recipient of a liver transplant.
- Presence or history of any condition that, in the view of the Investigator, would interfere with participation, pose undue risk, or would confound interpretation of results.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Prevalence of Anti-AAV8 Antibodies in Subjects with OTC Deficiency or GSDIa
Time Frame: Up to 35 days
|
Up to 35 days
|
|
Prevalence of Anti-AAV9 Antibodies in Subjects with Wilson Disease
Time Frame: Up to 35 days
|
Up to 35 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Medical Director, Ultragenyx Pharmaceutical Inc
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Metabolic Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Liver Diseases
- Genetic Diseases, Inborn
- Genetic Diseases, X-Linked
- Basal Ganglia Diseases
- Movement Disorders
- Neurodegenerative Diseases
- Carbohydrate Metabolism, Inborn Errors
- Metabolism, Inborn Errors
- Heredodegenerative Disorders, Nervous System
- Brain Diseases, Metabolic
- Brain Diseases, Metabolic, Inborn
- Amino Acid Metabolism, Inborn Errors
- Metal Metabolism, Inborn Errors
- Urea Cycle Disorders, Inborn
- Hepatolenticular Degeneration
- Ornithine Carbamoyltransferase Deficiency Disease
- Glycogen Storage Disease
Other Study ID Numbers
Other Study ID Numbers
- UX431-CL001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.